A novel angiomatoid epithelioid sarcoma cell line, Asra-EPS, forming tumors with large cysts containing hemorrhagic fluid  by unknown
Imura et al. BMC Research Notes 2013, 6:305
http://www.biomedcentral.com/1756-0500/6/305RESEARCH ARTICLE Open AccessA novel angiomatoid epithelioid sarcoma cell line,
Asra-EPS, forming tumors with large cysts
containing hemorrhagic fluid in vivo
Yoshinori Imura1, Norifumi Naka1,2*, Hidetatsu Outani1, Hirohiko Yasui1, Satoshi Takenaka1, Ken-ichiro Hamada1,
Ritsuro Ozaki1, Mitsunori Kaya3, Ken-ichi Yoshida4, Eiichi Morii4, Akira Myoui1 and Hideki Yoshikawa1Abstract
Background: Whereas we can use several human epithelioid sarcoma (ES) cell lines for basic and preclinical
research, an angiomatoid ES cell line has not been reported to date. We have treated a case of an angiomatoid ES
developing in the right upper extremity of a 67-year-old man.
Methods: An angiomatoid ES cell line, Asra-EPS was newly established and characterized for its morphology,
growth rate and chromosomal analysis. Tumorigenicity of Asra-EPS cells was also analyzed in athymic nude mice.
Results: Asra-EPS cells were round, polygonal or spindle-shaped with an abundant cytoplasm and have been
maintained continuously in vitro for over 150 passages during more than 15 months. These cells secreted cancer
antigen 125 (CA 125), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) into the culture medium.
Asra-EPS cells were tumorigenic when implanted in nude mice with tumors reaching a volume of 1000 mm3 at
around 50 days. Histological features of tumors formed in mice were essentially the same as those of the original
tumor, exhibiting a multinodular proliferation of eosinophilic epithelioid and spindle-shaped cells with prominent
areas of hemorrhage and blood-filled cystic spaces strikingly corresponding to the potential of hemorrhagic cyst
formation in the original tumor. They showed immunopositive staining for cytokeratins (AE1/AE3 and CAM5.2),
epithelial membrane antigen (EMA), vimentin, CD31, CD34 and CA 125, but negative for integrase interactor 1
(INI-1) and factor VIII-related antigen.
Conclusions: The established cell line represents a biologically relevant new tool to investigate the molecular
pathology of human angiomatoid ES and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.
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Epithelioid sarcoma (ES) was first described in 1970 by
Enzinger as a distinct soft tissue tumor with mixed epi-
thelial and mesenchymal phenotype, but the origin and
true nature of ES remain controversial [1]. In general, ES
is a relatively rare sarcoma and accounts for less than
1% of all soft tissue sarcoma [2]. The clinical course of
ES is usually characterized by local recurrence and the
potential for metastatic spread mostly to lymph nodes* Correspondence: nnaka@ort.med.osaka-u.ac.jp
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reproduction in any medium, provided the orand lung, but effective chemotherapy has not been
established [3,4]. Two main clinicopathologic types of
ES are recognized. The classic type manifests clinically
as a painless, slow-growing nodule arising within the
dermis or subcutis or, less commonly, in deep fascial or
tenosynovial tissue [4]. Usually, it occurs in young adults
at the flexor surface of the fingers, hand, wrist, and fore-
arm, followed by knee and lower leg. On the other hand,
the less common type, also known as the proximal type
or large cell/rhabdoid ES, occurs predominantly in
middle-aged or older adults in axial proximal locations
such as pelvis, mediastinum and trunk, as deep infiltra-
tive masses [5]. Additionally, other lesser common vari-
ants have been described, including the angiomatoidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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some case reports of angiomatoid ES, which distinctively
features cyst formation and hemorrhage within tumor
nodules, have been described [8,9]. To date, a small
number of ES cell lines have successfully been
established [10-21], but there is no cell line from
angiomatoid ES reported (Table 1). We herein present a
case of angiomatoid ES arising in a 67-year-old man and
establish an angiomatoid ES cell line from this patient.
In this study, we describe the characteristics of a newly
established angiomatoid ES cell line, Asra-EPS, both
in vitro and in vivo.
Methods
Case report
The patient was a 67-year-old Japanese man. Six months
before presentation to our institute, he noted a painful
soft tissue mass in his right elbow and was referred to
the primary hospital. He had no history of trauma or
other illness including hemorrhagic diathesis. The tumor
was diagnosed as a spontaneous hematoma since mag-
netic resonance imaging (MRI) revealed fluid-fluid level
collection. It had gradually increased in size over a 5-
month period. Pain was activity related initially and be-
came more constant later in the course. At the first
presentation to our hospital, he had a huge tumor meas-
uring 10 × 7 × 13 cm in his right upper extremity, with
intolerable pain, numbness, and nearly complete palsy at
the area of median and radial nerve in his hand. Blood
analyses revealed the data to be within normal limits ex-
cept for a marked elevation of C-reactive protein (CRP)
and cancer antigen 125 (CA 125). The serum CRP and
CA 125 levels were 7.52 mg/dl (normal: ≤ 0.2 mg/dl)
and 769 U/ml (normal: ≤ 35 U/ml), respectively. Re-
examined MRI showed large multinodular cystic tumorsTable 1 Clinical and cytogenetic findings in epithelioid sarcom
Cell line (year) Age/sex1 Primary location Do
RM-HS1 (1987) 37/M Left foot N.A
HX 165c (1988) 28/M Penis 38
GRU-1 (1990) 32/M Left buttock 29
SARCCR2 (1993) 33/F Knee 28
ES020488 (1993) 26/M Left forearm 60
VAESBJ (1995) 41/M Epidural space 32
ES-OMC-MN (1997) 44/F Right leg 68
YCUS-5 (1999) 3/F Neck N.A
SFT-8606 (2000) 75/M Left elbow N.A
FU-EPS-1 (2005) 21/M Right upper arm 45
NEPS (2010) 32/M Forearm N.A
Epi-544 (2011) N.A/N.A Foot 48
Asra-EPS (2013) 67/M Right elbow 38
1F female, M male. 1 2 3 4 5N.A data not available. 3N nude mice, S SCID mice.with satellite lesions in his right arm, infiltrating major
neurovascular structures (Figure 1A, B, C, D). Computed
tomography (CT) of the chest revealed no metastatic le-
sions in the lungs. Percutaneous needle biopsy was
performed and microscopic examination of the speci-
men exhibited a nodular growth pattern with central ne-
crosis, composed of compact sheets of epithelioid and
spindle-shaped cells. In parts, prominent areas of
hemorrhage and foci with blood-filled cystic spaces were
observed. A tentative histological diagnosis of epithelioid
angiosarcoma or angiomatoid ES was made. A right
above-elbow amputation was performed because of
high-grade malignancy and tumor infiltration into major
neurovascular structures. Macroscopically, large cyst
filled with coagulated blood occupied most part of the
amputated arm. Microscopic examination of the speci-
men revealed the same as percutaneous needle biopsy
(Figure 2A, B). Immunohistochemistry showed positivity
of tumor cells for cytokeratins (AE1/AE3 and CAM5.2)
(Figure 2C, D), epithelial membrane antigen (EMA) (Fig-
ure 2E), vimentin (Figure 2F), CD31 (Figure 2G), CD34
(Figure 2H) and CA 125 (Figure 2I) whereas integrase
interactor 1 (INI-1) and factor VIII-related antigen were
negative (Figure 2J, K), confirming the histological diag-
nosis as angiomatoid ES based mainly on the CA 125
and INI-1 immunoreactivity. Positive rate of Ki-67 was
approximately 50% (Figure 2L). Radiotherapy composed
of 60Gy/30fr was done between the right shoulder in-
cluding axilla and the stump of arm postoperatively in 5
weeks. Adjuvant chemotherapy was not administered
due to age based limitations. At 21 days after the oper-
ation, the serum CRP and CA 125 levels decreased to
0.03 mg/dl and 53 U/ml, respectively. Four months later,
concomitant with re-elevation of the serum CRP and
CA 125 levels, left axillary lymph node metastasis anda cell lines which have been established until now
ubling time2 Tumorigenicity3 CA1254 INI-15
N.A N.A N.A
h N N.A N.A
h N N.A N.A
h N N.A N.A
h N N.A N.A
h S - -
.5 h - N.A N.A
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Figure 1 MRI of the huge tumor in the right upper extremity of a 67-year-old man. (A) T1-weighted coronal image. (B) T2-weighted







Figure 2 Microscopic features of the patient’s original tumor. (A, B) Histological appearance of the original tumor. H&E staining showed a
multinodular proliferation of eosinophilic epithelioid and spindle-shaped cells with prominent areas of hemorrhage. (C-L) Immunohistochemical
reactivity in the original tumor. Tumor cells were diffusely positive for AE1/AE3 (C), CAM5.2 (D), EMA (E), vimentin (F), CD31 (G), CD34 (H) and CA
125 (I), but negative for INI-1 (J) and factor VIII-related antigen (K). Positive rate of Ki-67 was approximately 50% (L). Scale bars: 100μm.
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months after the primary surgery, the patient died of re-
spiratory insufficiency.
Establishment of a new cell line from an angiomatoid ES
Tumor cells were isolated from surgically resected tissues
with the patient’s informed consent and under the guide-
lines of the Institutional Review Board for Clinical Research
at Osaka University Hospital. The tumor tissues were
minced and incubated with 1 mg/ml of collagenase (Sigma-
Aldrich, St. Louis, MO, USA) for 1 h at 37°C. Cell suspen-
sions were passed through a 40-μm nylon mesh (Becton
Dickinson Falcon, Franklin Lakes, NJ, USA) and the tumor
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, Grand Island, NY, USA) with 10% fetal
bovine serum (FBS; Sigma). The adherent cells were
maintained for over 15 months in culture, and passed more
than 150 times. Attached cells exhibited spindle-shaped,
epithelioid and polygonal morphology. This cell line was
named Asra-EPS. Asra-EPS cells were cultured at 37°C
with 95% air, 5% CO2, and 100% humidity.
Cell growth assay
To determine the doubling time, 1 × 105 Asra-EPS cells
were seeded into each well of 6-well plates (BD Falcon) with
2 ml DMEM, supplemented with 10% FBS. Three wells
were trypsinized with 0.25% Trypsin plus EDTA (Invitrogen,
Carlsbad, CA, USA) every 24 h and cell number for each
well was counted with a hemocytometer for 8 days.
Soft agar colony formation assay
To determine the anchorage-independent cell growth abil-
ity, soft agar colony formation assay was performed. Asra-
EPS cells (5 × 103) were added to 0.5% SeaPlaque Agarose
(Lonza, Basel, Switzerland) in 1 ml DMEM with 10% FBS
over 0.6% agar in 2 ml DMEM with 10% FBS in 35 mm
plates (BD Falcon). For 3 weeks, plates were looked at
every day to make sure they have not dried out and add
growth medium to the plates when necessary.
CA 125, interleukin-6 (IL-6) and vascular endothelial
growth factor (VEGF) measurement in vitro
Resuspension of 1 × 105 cells were planted in 2 ml
DMEM supplemented with 10% FBS on 6-well plates. At
7th day, culture medium was collected and centrifuged
at 1200g for 5 min to remove floating cells, and then the
supernatant was stored at −80°C until assay. The con-
centration of CA 125, IL-6 and VEGF was measured by
the chemiluminescent enzyme immunoassay (CLEIA)
technique (SRL Inc., Tokyo, Japan).
Nude mice xenografting
Five-week-old athymic nude mice (BALB/c nu/nu; SLC,
Shizuoka, Japan) were housed at the Institute ofExperimental Animal Sciences Osaka University Medical
School, in accordance with guideline approved by the In-
stitutional Animal Care and Use Committee of Osaka
University Graduate School of Medicine. To determine
the tumorigenicity of Asra-EPS cell line in vivo, 1 × 107
cells were injected subcutaneously into the left side of
back. Mice were inspected twice a week and were
sacrificed when the total tumor burden reached 2 cm3.
Tumor size was measured with a caliper and tumor vol-
ume calculated by the formula (a × b2)/2, with a being
the longest diameter and b the shortest diameter of the
tumor. Tumors were then resected for immunohisto-
chemical studies.
Immunohistochemistry
Immunohistochemical studies were performed to con-
firm whether the phenotype of the cultured cells
matched with that of the original tumor cells. Specimens
of the original tumor and of the tumors formed in nude
mice were fixed in 10% neutral, buffered formalin, em-
bedded in paraffin, sectioned at 4 μm thickness, and
stained with hematoxylin and eosin (H&E). Paraffin-
embedded sections were deparaffinized and dehydrated.
Antigens were retrieved at 95°C for 15 min in 10 mM
citrate buffer. After blocking of endogenous peroxidase
activity for 10 min with methanol containing 3% H2O2,
the sections were reacted for 1 h with phosphate-
buffered saline (PBS) containing 2% bovine serum albu-
min (BSA) at room temperature to prevent nonspecific
binding. They were then incubated overnight with pri-
mary antibodies at 4°C. Primary antibodies against AE1/
AE3 (1:100, Dako, Glostrup, Denmark), CAM5.2 (BD
Biosciences, San Jose, CA, USA), EMA (1:100, Dako),
vimentin (1:100, Abcam, Cambridge, UK), CD31 (1:50,
Dako), CD34 (1:100, Leica Microsystems, Wetzlar,
Germany), CA 125 (1:50, Dako), INI-1 (1:50, BD Biosci-
ences), factor VIII-related antigen (1:50, Dako) and Ki-
67(1:75, Dako) were used. On the next day, the sections
were incubated for 1 h with horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:500, BD Bio-
sciences) and stained with 3,3′-diaminobenzidine
tetrahydrochloride (DAB; Dako). The sections were fi-
nally counterstained with hematoxylin. As a negative
control, staining was carried out in the absence of pri-
mary antibody.
Western blotting
Equal amounts of protein extracted from cultured cells
were separated on 4-12% Bis-Tris gels (Invitrogen) and
transferred to PVDF membranes. The membranes were
rinsed in Tris-buffered saline containing 0.1% Tween
(TBS-T) and incubated in blocking buffer (5% skim milk
in TBS-T) at room temperature. The blocked mem-


















Figure 3 Characteristics of Asra-EPS cells in vitro. (A)
Morphology of Asra-EPS cells under 2D culture by phase-contrast
microscopy. (B) Growth curve of Asra-EPS cells in vitro. Each point
represents the mean value ± standard deviation (SD) (n=3). (C)
Colony formation of Asra-EPS cells in soft agar. Scale bars: 100μm.
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technology, Inc., Santa Cruz, CA, USA) at 4°C overnight
and washed with TBS-T 3 times for 5 min each time,
followed by incubation with HRP-conjugated second
antibodies (1:2000) at room temperature for 1 h. After
washing in TBS-T, the immunoreactive bands were visu-
alized using enhanced chemiluminescence (ECL) (Perkin
Elmer Life Sciences, Waltham, MA, USA).
Chromosome analysis
Metaphase chromosome spreads from Asra-EPS cells
were prepared according to standard procedures. Asra-
EPS cells were treated with 20 μg/ml of colcemide over-
night and harvested. After treatment of 0.075 M KCl for
20 min at 37°C, cells were fixed 3 times with methanol
and acetic acid (3:1) and fixed cells were spread on slides.
Multicolor fluorescence in situ hybridization (mFISH)
was performed using commercially available mFISH kits
(MetaSystems, Altlussheim, Germany) according to the
manufacturer’s protocol. Briefly metaphase spreads were
hardened 70°C for 2 h. After applying mFISH probes on
the metaphase spreads, co-denaturation of target DNA
with probe DNA was performed at 70°C for 5 min,
followed by 72 h incubation at 37°C to allow
hybridization of the probes. The slides were then washed
twice with 50% formamide/2 × standard saline citrate
(SSC) solution for 20 min at 37°C, 2 × SSC for 10 min
at room temperature and 1 × SSC for 10 min. The
slides were then counterstained with 4′,6-diamidino-2-
phenylindole (DAPI) and mounted. Separate fluoro-
chrome images were captured using a Leica DC 350FX
cooled CCD camera (Leica) mounted on a Leica DMRA2
microscope using Leica CW4000 FISH software. The im-
ages were analyzed using Leica CW4000 karyo (Leica).
Results
Cell morphology and colony formation in 2D and 3D
culture models
The cell line Asra-EPS has now been growing in stand-
ard 2D culture without interruption for over 15 months
and has been passed at least 150 times. The line
appeared to contain epithelial-like polygonal cells but, in
addition, more mesenchymal-like spindle-shaped cells
were apparent (Figure 3A). Both of these morphological
phenotypes appeared to be stable with repeated passa-
ging. Asra-EPS cells showed excellent growth without
contact inhibition. The doubling time of Asra-EPS cells
in logarithmic growth phase was approximately 38 h
(Figure 3B). Asra-EPS cells could form colonies in soft
agar (Figure 3C).
Tumorigenicity of Asra-EPS cells in nude mice
Fourteen days after injection of 1 × 107 Asra-EPS cells
into the nude mice, tumor growth was evident in all 5mice tested. The efficiency of tumor formation was ex-
tremely high. These tumors were serially transplantable in
further mice as a stable xenograft line. The tumors were
then resected, digested, and plated into dishes. These re-
plated cells showed similar morphological features to the
original cells from the patient tumor tissues. Eight weeks
after injection of Asra-EPS cells, the average of Asra-EPS
tumor volume was 1514 mm3 (Figure 4A). Asra-EPS tu-
mors formed in mice also exhibited blood-filled cyst for-
mation within them as they grew largely, reflecting the
clinical feature of the original tumor (Figure 4B).
Morphologic characteristics of Asra-EPS tumors
H&E staining of Asra-EPS xenograft tumors with cysts
formation and a wide range of hemorrhage demon-
strated histological appearances resembling the original
tumor (Figure 5A, B, C). The immunohistochemical pro-
files of both tissues from the patient tumor tissues and
from Asra-EPS tumors formed in mice were the same as
previous studies on human angiomatoid ES tissues [8,9].
Asra-EPS tumors exhibited positive staining for AE1/
AE3 (Figure 5D), CAM5.2 (Figure 5E), EMA (Figure 5F),
vimentin (Figure 5G), CD31 (Figure 5H), CD34
(Figure 5I) and CA 125 (Figure 5J), but negative staining
for INI-1 (Figure 5K) and factor VIII-related antigen
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Figure 4 Characteristics of Asra-EPS tumors in vivo. (A) Growth
curve of Asra-EPS tumors in nude mice. Each point represents the
mean value ± SD (n=5). (B) Asra-EPS tumors with large cysts
containing hemorrhagic fluid (black arrow).
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50% (Figure 5M). In western blotting, no INI-1 expres-
sion was found in Asra-EPS cells, in contrast to the syn-
ovial sarcoma cell line Yamato-SS [22], which was used
as a control (Figure 6).
Secretion of CA 125, IL-6 and VEGF by Asra-EPS cells
in vitro
Amounts of CA 125, IL-6 and VEGF secreted into the
culture medium of 1 × 105 Asra-EPS cells at 7th day cul-
ture were as follows: CA 125 145 U/ml; IL-6 7760
pg/ml; VEGF 957 pg/ml. Asra-EPS cells produced CA
125, IL-6 and VEGF at high levels.
Chromosome analysis
In the chromosomal analysis, 50 metaphases were exam-
ined. The chromosome number of Asra-EPS cells at the
30th passage ranged from 45 to 133, with a mode of 90.
The karyotype of Asra-EPS showed near-tetraploidy with
some chromosomal translocations and fragments (Figure 7).
No recurrent chromosomal translocation was detected.
Discussion
Angiomatoid ES is less common variant of ES and its
clinical features are still unknown [8,9]. Histologically,the tumor of angiomatoid ES is composed of epithelioid
and spindle-shaped tumor cells exhibiting intracytoplasmic
vacuoles reminiscent of intracytoplasmic vascular lumen
formation [23]. The morphology of the tumor cells is simi-
lar to that seen in classical ES. Angiomatoid ES shows
prominent areas of hemorrhage and foci with blood-filled
cystic spaces within the tumor [8,23]. These features
closely resemble those seen in malignant vascular tumors
with epithelioid cytomorphology, including epithelioid
angiosarcoma and epithelioid hemangioendothelioma [24].
In this study, we have succeeded in establishing an
angiomatoid ES cell line, called Asra-EPS. To the best of
our knowledge, this is the first report of establishing and
characterizing an angiomatoid ES cell line. Asra-EPS
cells exhibited the morphology of epithelial-like polyg-
onal cells and mesenchymal-like spindle-shaped cells.
Asra-EPS cell line had epithelial and mesenchymal fea-
tures similar to those of the original tumor as revealed
by immunohistochemistry, secreted CA 125, IL-6 and
VEGF, did not express INI-1, and exhibited tumorigen-
icity in nude mice.
CA 125 is a tumor antigen forming the basis for a
serum assay widely used to monitor the clinical status of
patients with ovarian cancer [25,26]. Recently, elevated
serum CA 125 was reported in two patients with ES
[27]. Furthermore, a subsequent study by the same
group indicated that 10 of their 11 cases of ES (classic
type: 9 cases; proximal type: 1 case) showed strong im-
munoreactivity for CA 125 in the tumor cells [28].
Therefore, CA 125 could be considered to be a generally
useful tumor marker for diagnosing ES and monitoring
its clinical course. Nevertheless, it is unknown whether
CA 125 would be a useful marker for diagnosing and
monitoring the course of angiomatoid ES.
IL-6 is presently considered as the most important
mediator of acute-phase protein synthesis in hepatocytes
and cell culture experiments have suggested that IL-6
stimulates the synthesis of serum CRP [29-31]. A clas-
sical ES cell line, designated as ES-OMC-MN, was
reported to produce IL-6, but not to be tumorigenic in
nude mice [17]. In this study, we showed that Asra-EPS
could constitutively produce CA 125 and IL-6. In this
case, blood analyses showed significantly high levels of
CA 125 and CRP in the sera before the surgery and
rapid decline of those levels to the normal range after
the surgery. At the recurrence, the serum levels of CA
125 and CRP were re-elevated. Taken together, these
clinical findings indicated that the measurement of
serum CA 125 and CRP could be recommended to diag-
nose angiomatoid ES and monitor its clinical course.
INI-1 is the protein product of the hSNF5/INI1/
SMARCB1/BAF47 gene as a tumor suppressor gene lo-
cated on 22q11.2 that is characteristically inactivated in









Figure 5 Microscopic features of Asra-EPS tumors formed in nude mice. (A-C) Histological appearance of Asra-EPS tumors (H&E).
Histological features of Asra-EPS tumors were almost the same as those of the original tumor. (D-M) Immunohistochemical reactivity in Asra-EPS
tumors. Tumor cells were diffusely positive for AE1/AE3 (D), CAM5.2 (E), EMA (F), vimentin (G), CD31 (H), CD34 (I) and CA 125 (J), but negative







Figure 6 No INI-1 expression of Asra-EPS.
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imal type, were reported to show complete loss of expres-
sion of INI-1 [36]. The present study demonstrated that
INI-1 protein expression was also lost in the original
tumor as well as our established angiomatoid ES cell line.
INI-1 expression is retained in most of epithelioid
angiosarcoma and epithelioid hemangioendothelioma.
Thereby, the immunohistochemical profile of the
angiomatoid ES was useful to differentiate them from ma-
lignant epithelioid vascular tumors with INI-1 and CA
125 immunoreactivity [21]. Asra-EPS cell line might pro-
vide us with a research material to elucidate the mechan-
ism in the loss of INI-1 protein expression and its
oncogenic functions in ES pathogenesis.
Surprisingly, Asra-EPS tumors formed in nude mice
also showed prominent areas of hemorrhage and foci
with blood-filled cystic spaces as they grew largely. Their
Figure 7 Representative karyotype of Asra-EPS at the 30th passage. It is 90, XXYY, -4, +5, +8, +9, -10, -13, t(13;15), +14, -15, -15, -20, -22,
-22, +1mar.
Imura et al. BMC Research Notes 2013, 6:305 Page 8 of 9
http://www.biomedcentral.com/1756-0500/6/305pathological appearance of cystogenesis in Asra-EPS
closely resembles that of the original tumor. While
OVCAR-3, one of ovarian cancer cell lines, has no po-
tential to form the cysts itself [37], Duyndam and col-
league reported that VEGF165-overexpression induced
OVCAR-3 xenograft tumors to form the cysts
containing hemorrhagic fluid and that VEGF165 might
play a role in the cystogenesis [38]. To our knowledge,
there is no report of cancer or sarcoma cell lines to
spontaneously generate cysts within the xenograft tu-
mors in vivo, except for the above described genetically
engineered cancer cell line. Therefore, Asra-EPS is the
first sarcoma cell line, with the potential to form tumors
with large cysts containing hemorrhagic fluid in nude
mice. Since Asra-EPS secreted a considerable amount of
VEGF, molecular target drugs against VEGF might be ef-
fective to suppress the cystogenesis in Asra-EPS xeno-
graft tumors. However, bevacizumab (Genentech/Roche,
South San Francisco, CA, USA), a humanized monoclo-
nal antibody to human VEGF, could not inhibit the for-
mation of cysts in Asra-EPS tumors (data not shown).
Collectively, these findings suggested that other growth
factors than VEGF or cytokines might contribute to the
cystogenesis in Asra-EPS tumors and further investiga-
tion is needed to clarify the molecular mechanism of
cyst formation.
Conclusions
A newly established Asra-EPS cell line fully preserved
the morphological and biochemical characteristics of theoriginal tumor diagnosed as angiomatoid ES. Asra-EPS
is an excellent tool for further investigation of the nature
of angiomatoid ES, the mechanism in the formation of
cyst, and potential therapies for patients with ES.
Abbreviations
BSA: Bvine serum albumin; CA 125: Cancer antigen 125;
CLEIA: Chemiluminescent enzyme immunoassay; CRP: C-reactive protein;
CT: Computed tomography; DAB: 3,3′-diaminobenzidine tetrahydrochlorid;
DAPI: 4′6-diamidino-2-phemylindole; DMEM: Dulbecco’s modified Eagle’s
medium; ECL: Enhanced chemiluminescence; EMA: Epithelial membrane
antigen; ES: Epithelioid sarcoma; FBS: Fetal bovine serum; H&E: Hematoxylin
and eosin; HRP: Horseradish peroxidase; IL-6: Interleukin-6; INI-1: Integrase
interactor 1; mFISH: multicolor fluorescence in situ hybridization;
MRI: Magnetic resonance imaging; MRT: Malignant rhabdoid tumor;
PBS: Phosphate-buffered saline; SSC: Standard saline citrate; TBS-T: Tris-
buffered saline containing 0.1% Tween; VEGF: Vascular endothelial
growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YI carried out the whole study and drafted the manuscript. YI and NN
designed the study. NN revised the manuscript. NN, ST and RO operated the
patient. NN, RO and MK treated the patient. HO, HY, ST, KH, AM and HY
helped to draft the manuscript. KY and EM performed the pathological
examination. All authors read and approved the final manuscript.
Acknowledgements
Written informed consent was obtained from the patient’s next of kin for
publication of this manuscript and accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
We thank Mari Shinkawa and Asa Tada for their excellent technical
assistance. This study was supported in part by grant-in -aid from the
Ministry of Education, Science, and Culture, Japan (No. 24592233).
Imura et al. BMC Research Notes 2013, 6:305 Page 9 of 9
http://www.biomedcentral.com/1756-0500/6/305Author details
1Department of Orthopaedic Surgery, Osaka University Graduate School of
Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. 2Department of
Biology, Osaka Medical Center of Cancer and Cardiovascular Diseases, 1-3-3
Nakamichi, Higashinari-ku, Osaka 537-8511, Japan. 3Department of
Orthopaedic Surgery, Chitose City Hospital, 2-1-1 Hokko, Chitose, Hokkaido
066-8550, Japan. 4Department of Pathology, Osaka University Graduate
School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Received: 23 April 2013 Accepted: 29 July 2013
Published: 1 August 2013
References
1. Enzinger FM: Epithelioid sarcoma. A sarcoma simulating a granuloma or
carcinoma. Cancer 1970, 26:1029–1041.
2. de Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer
AJ, Hoekstra HJ: Epithelioid sarcoma: still an only surgically curable
disease. Cancer 2006, 107:606–612.
3. Chase DR, Enzinger FM: Epithelioid sarcoma: diagnosis, prognostic
indicators, and treatment. Am J Surg Pathol 1985, 9:241–263.
4. Halling AC, Wollen PC, Pritchard DJ, Vlasak R, Nascimento AG: Epithelioid sarcoma:
a clinicopathologic review of 55 cases. Mayo Clin Med 2004, 71:636–642.
5. Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD: “Proximal-type”
epithelioid sarcoma: a distinctive aggressive neoplasm showing
rhabdoid features, clinicopathologic, immunohistochemical, and
ultrastructural study of a series. Am J Surg Pathol 1997, 21:130–146.
6. Von Hochstetter AR, Meyer VE, Grant JW, Honegger HP, Schreiber A:
Epithelioid sarcoma mimicking angiosarcoma: the value of
immunohistochemistry in the differential diagnosis. Virchows Arch A
Pathol Anat Histopathol 1991, 418:271–278.
7. Mirra JM, Kessler S, Bhuta S, Eckardt J: The fibroma-like variant of epithelioid
sarcoma. A fibrohistiocytic/myoid cell lesion often confused with benign
and malignant spindle cell tumors. Cancer 1992, 69:1382–1395.
8. Kaddu S, Wolf I, Horn M, Kerl H: Epithelioid sarcoma with angiomatoid
features: report of an unusual case arising in an elderly patient within a
burn scar. J Cutan Pathol 2008, 35:324–328.
9. Brassesco MS, Valera ET, Castro-Gamero AM, Moreno DA, Silveira TP, Mori
BM, Engel EE, Scrideli CA, Tone LG: Cytogenetic findings in an epithelioid
sarcoma with angiomatoid features. A case report. Genet Mol Res 2009,
8:1211–1217.
10. Reeves BR, Fisher C, Smith S, Courtenay VD, Robertson D: Ultrastructural,
immunocytochemical and cytogenetic characterization of a human
epithelioid sarcoma cell line (RM-HS1). J Natl Cancer Inst 1987, 78:7–18.
11. Kelland LR, Bingle L: Radiosensitivity and characterization of a newly
established cell line from an epithelioid sarcoma. Br J Cancer 1988, 58:322–325.
12. Gerharz CD, Moll R, Ramp U, Mellin W, Gabbert HE: Multidirectional
differentiation in a newly established human epithelioid sarcoma cell
line (GRU-1) with co-expression of vimentin, cytokeratin and
neurofilament proteins. Int J Cancer 1990, 45:143–152.
13. Roche H, Julia AM, Jozan S, Muller C, Dastugue N, Arquier MA, Marques B,
Laurent G, Canal P: Characterization and chemosensitivity of a human
epithelioid sarcoma cell line (SARCCR 2). Int J Cancer 1993, 54:663–668.
14. Sonobe H, Furihata M, Iwata J, Oka T, Ohtsuki Y, Hamasato S, Fujimoto S:
Morphological characterization of a new human epithelioid sarcoma cell line,
ES020488, in vitro and in vivo. Virchows Arch B Cell Pathol 1993, 63:219–225.
15. Helson C, Melamed M, Braverman S, Traganos F, Preti R, Helson L: VA-ES-BJ:
an epithelioid sarcoma cell line. Int J Oncol 1995, 7:51–56.
16. Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, Kaneko Y, Yoh S, Emoto G,
Kikuchi M: Epithelioid sarcoma with an 18q aberration. Cancer Genet
Cytogenet 1996, 91:46–52.
17. Kusakabe H, Sakatani S, Yonebayashi K, Kiyotake K: Establishment and
characterization of an epithelioid sarcoma cell line with an autocrine
response to interleukin-6. Arch Dermatol Res 1997, 289:224–233.
18. Goto H, Takahashi H, Funabiki T, Ikuta K, Sasaki H, Nagashima Y: Neural
differentiation of a novel cell line, YCUS-5, established from proximal-
type epithelioid sarcoma of a child. Med Pediatr Oncol 1999, 33:137–138.
19. Nishio J, Iwasaki H, Nabeshima K, Ishiguro M, Naumann S, Isayama T, Naito
M, Kaneko Y, Kikuchi M, Bridge JA: Establishment of a new human
epithelioid sarcoma cell line, FU-EPS-1: molecular cytogenetic
characterization by use of spectral karyotyping and comparative
genomic hybridization. Int J Oncol 2005, 27:361–369.20. Hoshino M, Kawashima H, Ogose A, Kudo N, Ariizumi T, Hotta T, Umezu H,
Hatano H, Morita T, Nishio J, Iwasaki H, Endo N: Serum CA 125 expression
as a tumor marker for diagnosis and monitoring the clinical course of
epithelioid sarcoma. J Cancer Res Clin Oncol 2010, 136:457–464.
21. Sakharpe A, Lahat G, Gulamhusein T, Liu P, Bolshakov S, Nguyen T, Zhang P,
Belousov R, Young E, Xie X, Rao P, Hornick JL, Lazar AJ, Pollock RE, Lev D:
Epithelioid sarcoma and unclassified sarcoma with epithelioid features:
clinicopathological variables, molecular markers, and a new
experimental model. Oncologist 2011, 16:512–522.
22. Naka N, Takenaka S, Araki N, Miwa N, Hashimoto N, Yoshioka K, Joyama S,
Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K: Synovial
sarcoma is stem cell malignancy. Stem Cells 2010, 28:1119–1131.
23. Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF:
Epithelioid sarcoma. An immunohistochemical analysis of 112 classical
and variant cases and a discussion of the differential diagnosis. Hum
Pathol 1999, 30:934–942.
24. Von Hochstetter AR, Meyer VE, Grant JW, Honegger HP, Schreiber A:
Epithelioid sarcoma mimicking angiosarcoma. The value of
immunohistochemistry in the differential diagnosis. Virchows Arch Pathol
Anat Histopathol 1991, 418:271–278.
25. Yin BW, Dniatrian A, Lloyd KO: Ovarian cancer antigen CA125 is encoded
by the MUC16 mucin gene. Int J Cancer 2002, 98:737–740.
26. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA,
Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New
tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15:274–281.
27. Kato H, Hatori M, Watanabe M, Kokubun S: Epithelioid sarcoma with elevated
serum CA125: report of two cases. Jpn J Clin Oncol 2003, 33:141–144.
28. Kato H, Hatori M, Kokubun S, Watanabe M, Smith RA, Hotta T, Ogose A,
Morita T, Murakami T, Aiba S: CA125 expression in epithelioid sarcoma.
Jpn J Clin Oncol 2004, 34:149–154.
29. Shine B, de Beer FC, Pepys MB: Solid phase radioimmunoassays for
human C-reactive protein. Clin Chim Acta 1981, 117:13–23.
30. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB: Measurement
of serum C-reactive protein concentration in myocardial ischaemia and
infarction. Br Hearl J 1982, 47:239–243.
31. Castell JV, Gomez-Lechon ML, David M, Andus T, Geiger T, Trullenque R, Fabra
R, Heinrich PC: Interleukin-6 is the major regulator of acute phase protein
synthesis in adult human hepatocytes. FEBS Lett 1989, 242:237–239.
32. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P,
Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1
in aggressive paediatric cancer. Nature 1998, 394:203–206.
33. Bourdeaut F, Freneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Pierron G,
Sainte-Rose C, Bergeron C, Bouvier R, Rialland X, Laurence V, Michon J,
Sastre-Garau X, Delattre O: hSNF5/INI1-deficient tumours and rhabdoid
tumours are convergent but not fully overlapping entities. J Pathol 2007,
211:323–330.
34. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP: Binding and
stimulation of HIV-1 integrase by a human homolog of yeast
transcription factor SNF5. Science 1994, 266:2002–2006.
35. Ae K, Kobayashi N, Sakuma R, Ogata T, Kuroda H, Kawaguchi N, Shinomiya
K, Kitamura Y: Chromatin remodeling factor encoded by ini1 G1 arrest
and apotosis in ini1-deficient cells. Oncogene 2002, 21:3112–3120.
36. Hornick JL, Dal Cin P, Fletcher CD: Loss of INI1 expression is characteristic
of both conventional and proximal-type epithelioid sarcoma. Am J Surg
Pathol 2009, 33:542–550.
37. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW,
Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a
human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and
estrogen receptors. Cancer Res 1983, 43:5379–5389.
38. Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G,
Pinedo HM, Boven E: Vascular endotherial growth factor-165
overexpression stimulates angiogenesis and induces cyst formation and
macrophage infiltration in human ovarian cancer xenografts. Am J Pathol
2002, 160:537–548.
doi:10.1186/1756-0500-6-305
Cite this article as: Imura et al.: A novel angiomatoid epithelioid
sarcoma cell line, Asra-EPS, forming tumors with large cysts containing
hemorrhagic fluid in vivo. BMC Research Notes 2013 6:305.
